MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenzavirus B Infections.
Sat.Nov 18, 2023
52 
LuAG-09222 by H. Lundbeck for Migraine: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
LuAG-09222 is under clinical development by H. Lundbeck and currently in Phase II for Migraine.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Increase Revenue With Better, Faster Sales Onboarding
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Risk adjusted net present value: What is the current valuation of Medivir’s Fostroxacitabine Bralpamide Hydrochloride?
Pharmaceutical Technology
NOVEMBER 18, 2023
Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.
Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?
Pharmaceutical Technology
NOVEMBER 18, 2023
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals’s RPA-501?
Pharmaceutical Technology
NOVEMBER 18, 2023
RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).
Rilzabrutinib by Principia Biopharma for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia.
Mirikizumab by Eli Lilly and Co for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Mirikizumab is under clinical development by Eli Lilly and Co and currently in Phase III for Crohn's Disease (Regional Enteritis).
Risk adjusted net present value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.?
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.
Risk adjusted net present value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.?
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.
Tusamitamab ravtansine by Sanofi for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
APHD-012 by Aphaia Pharma for Pre-Diabetes/Impaired Glucose Tolerance: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
APHD-012 is under clinical development by Aphaia Pharma and currently in Phase II for Pre-Diabetes/Impaired Glucose Tolerance.
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections.
Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?
Pharmaceutical Technology
NOVEMBER 18, 2023
Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?
Pharmaceutical Technology
NOVEMBER 18, 2023
Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.
Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?
Pharmaceutical Technology
NOVEMBER 18, 2023
KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.
Risk adjusted net present value: What is the current valuation of Bavarian Nordic’s PXVX-0317?
Pharmaceutical Technology
NOVEMBER 18, 2023
PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Phase III program in Chikungunya Fever.
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Solid Tumor.
Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?
Pharmaceutical Technology
NOVEMBER 18, 2023
Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.
Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?
Pharmaceutical Technology
NOVEMBER 18, 2023
Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.
Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.
Amphotericin B by Cystetic Medicines for Cystic Fibrosis: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Amphotericin B is under clinical development by Cystetic Medicines and currently in Phase I for Cystic Fibrosis.
Tusamitamab ravtansine by Sanofi for Endometrial Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Endometrial Cancer.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PF-07257876 by Pfizer for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
PF-07257876 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Carcinoma.
Tusamitamab ravtansine by Sanofi for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Colorectal Cancer.
Tusamitamab ravtansine by Sanofi for Pancreatic Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Pancreatic Cancer.
Tusamitamab ravtansine by Sanofi for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Cervical Cancer.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Let's personalize your content